SCHEMBL14737238

SCHEMBL14737238

CON(C)C(=O)C(CNC(=O)O)OCc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 1/20 0.42
MMP8 P22894 1/20 0.42
ABCB1 P08183 2/20 0.39
PSMB5 P28074 1/20 0.39
ALDH1A1 P00352 3/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
APP P05067 1/20 0.38
SLC1A3 P43003 2/20 0.38
SLC1A2 P43004 2/20 0.38
SLC1A1 P43005 2/20 0.38
MEN1 O00255 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 1/20 0.38
FAAH O00519 1/20 0.37
HDAC2 Q92769 2/20 0.36
CTSL P07711 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12183918 0.86 SYK (0.52) CTSLCTSBCTSSCTSK
SCHEMBL31757921 0.77 MMP9 (0.47) MMP9MMP8ALDH1A1MAPTHPGD
SCHEMBL31757799 0.77 MMP9 (0.47) MMP9MMP8ALDH1A1MAPTHPGD
SCHEMBL14795053 0.76 MMP9 (0.43) MMP9MMP8ALDH1A1MAPTHPGD
SCHEMBL17825622 0.75 KMT2A (0.41) ALDH1A1HPGDMEN1KMT2AFAAH
SCHEMBL23911895 0.73 CTSS (0.51) ALDH1A1MEN1KMT2ACTSLCTSB
SCHEMBL6342824 0.72 KCNA3 (0.42) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL6493954 0.72 TRPV1 (0.46) MAPTCYP1A2CYP2C9
SCHEMBL22982284 0.71 MEN1 (0.47) ALDH1A1MEN1KMT2ACTSLCTSB
SCHEMBL5172763 0.71 MEN1 (0.47) ALDH1A1MEN1KMT2ACTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130059830-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME CORP 2013-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059830-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS PRCP, PREP, ENPEP MMP9 267/4885MMP8 1277/4885ABCB1 1582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.